Gu L, Sun Y, Bai T, Shao S, Tang S, Xue P
J Nanobiotechnology. 2025; 23(1):212.
PMID: 40089774
DOI: 10.1186/s12951-025-03284-3.
Rostami Ravari N, Sadri F, Mahdiabadi M, Mohammadi Y, Ourang Z, Rezaei Z
Front Cell Dev Biol. 2025; 13:1522873.
PMID: 40078365
PMC: 11897296.
DOI: 10.3389/fcell.2025.1522873.
Chen S, Shyu I, Chi J
Cancers (Basel). 2025; 17(5).
PMID: 40075648
PMC: 11898531.
DOI: 10.3390/cancers17050800.
He Y, Lin Y, Song J, Song M, Nie X, Sun H
Cell Commun Signal. 2025; 23(1):125.
PMID: 40055721
PMC: 11889974.
DOI: 10.1186/s12964-025-02121-2.
Du B, Fu Q, Yang Q, Yang Y, Li R, Yang X
Cell Death Discov. 2025; 11(1):87.
PMID: 40044643
PMC: 11883039.
DOI: 10.1038/s41420-025-02372-5.
PRMT5-mediated arginine methylation stabilizes GPX4 to suppress ferroptosis in cancer.
Fan Y, Wang Y, Dan W, Zhang Y, Nie L, Ma Z
Nat Cell Biol. 2025; .
PMID: 40033101
DOI: 10.1038/s41556-025-01610-3.
Identification of FZD7 as a potential ferroptosis-related diagnostic gene in endometriosis by bioinformatics analysis.
Huang J, Li J, Li X, Guo H, Chen S
Sci Rep. 2025; 15(1):7172.
PMID: 40021920
PMC: 11871347.
DOI: 10.1038/s41598-025-90803-9.
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors.
Du F, Wang G, Dai Q, Huang J, Li J, Liu C
Biomark Res. 2025; 13(1):35.
PMID: 40012016
PMC: 11866848.
DOI: 10.1186/s40364-025-00748-4.
Ferroptosis in Pulmonary Disease and Lung Cancer: Molecular Mechanisms, Crosstalk Regulation, and Therapeutic Strategies.
Guo D, Cai S, Deng L, Xu W, Fu S, Lin Y
MedComm (2020). 2025; 6(3):e70116.
PMID: 39991627
PMC: 11847630.
DOI: 10.1002/mco2.70116.
Iron and ferroptosis in kidney disease: molecular and metabolic mechanisms.
Wang W, Chen J, Zhan L, Zou H, Wang L, Guo M
Front Immunol. 2025; 16:1531577.
PMID: 39975561
PMC: 11835690.
DOI: 10.3389/fimmu.2025.1531577.
Bio-nanocomplexes impair iron homeostasis to induce non-canonical ferroptosis in cancer cells.
Wang X, Zhang T, Wang S, Shi H, Dong H, Huang Y
J Nanobiotechnology. 2025; 23(1):121.
PMID: 39972473
PMC: 11837358.
DOI: 10.1186/s12951-025-03117-3.
A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development.
Schneider A, Koppe C, Crouchet E, Papargyriou A, Singer M, Buttner V
Nat Commun. 2025; 16(1):1765.
PMID: 39971907
PMC: 11839950.
DOI: 10.1038/s41467-025-56493-7.
Based on bioinformatics, SESN2 negatively regulates ferroptosis induced by ischemia reperfusion via the System Xc-/GPX4 pathway.
Hu J, Qin L, Zhu G, Ren J, Wang H, Jin J
Front Genet. 2025; 15:1504114.
PMID: 39944356
PMC: 11814456.
DOI: 10.3389/fgene.2024.1504114.
Application of Nanomaterial-Mediated Ferroptosis Regulation in Kidney Disease.
Zhu J, Zhang Z, Chu Y, Xie Z, Zeng D, Jin L
Int J Nanomedicine. 2025; 20:1637-1659.
PMID: 39931533
PMC: 11808220.
DOI: 10.2147/IJN.S496644.
Insights on the crosstalk among different cell death mechanisms.
Eskander G, Abdelhamid S, Wahdan S, Radwan S
Cell Death Discov. 2025; 11(1):56.
PMID: 39929794
PMC: 11811070.
DOI: 10.1038/s41420-025-02328-9.
The complexities of cell death mechanisms: a new perspective in systemic sclerosis therapy.
Xia X, Kong C, Zhao X, Zhao K, Shi N, Jiang J
Apoptosis. 2025; .
PMID: 39924583
DOI: 10.1007/s10495-025-02082-4.
Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis.
Shen X, Chen Y, Tang Y, Lu P, Liu M, Mao T
Cell Rep Med. 2025; 6(2):101928.
PMID: 39879992
PMC: 11866519.
DOI: 10.1016/j.xcrm.2025.101928.
Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease.
Mao Y, Chen H, Zhu W, Ni S, Luo S, Tang S
J Inflamm Res. 2025; 18:883-894.
PMID: 39867947
PMC: 11760270.
DOI: 10.2147/JIR.S498340.
Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application.
Imam M, Ji J, Zhang Z, Yan S
Front Pharmacol. 2025; 15:1493188.
PMID: 39867656
PMC: 11757020.
DOI: 10.3389/fphar.2024.1493188.
CASC8 activates the pentose phosphate pathway to inhibit disulfidptosis in pancreatic ductal adenocarcinoma though the c-Myc-GLUT1 axis.
Yao H, Ge J, Chen J, Tang X, Li C, Hu X
J Exp Clin Cancer Res. 2025; 44(1):26.
PMID: 39865281
PMC: 11771065.
DOI: 10.1186/s13046-025-03295-w.